Sumanta K. Pal, MD, of City of Hope, and A. Oliver Sartor, MD, of Tulane University School of Medicine, discuss the implications of findings on black and white patients with metastatic castrate-resistant prostate cancer treated with abiraterone acetate and prednisone (Abstract LBA5009).
Danny Rischin, MD, of Peter MacCallum Cancer Centre, discusses phase II study findings on cemiplimab, a human monoclonal anti–PD-1 antibody, in patients with metastatic cutaneous squamous cell carcinoma (Abstract 9519).
Tony Mok, MD, of the Chinese University of Hong Kong, discusses study findings on dacomitinib vs gefitinib for first-line treatment of advanced non–small cell lung cancer, a final overall survival analysis.
Michael Gnant, MD, of the Medical University of Vienna, discusses study findings on adjuvant denosumab in early breast cancer––a disease-free survival analysis of postmenopausal patients.
Lee S. Schwartzberg, MD, of West Cancer Center, reports on the progress of the ACCC Immuno-Oncology Institute to speed adoption of immunotherapeutics in community practices.
Rita Elias Assi, MD, of The University of Texas MD Anderson Cancer Center, discusses the impact of next-generation sequencing on treatment selection in acute myeloid leukemia (Abstract 103).
